AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?
by Christopher Vargas
Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
Should You Buy AbbVie (ABBV) Ahead of Earnings?
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.
Use Rising P/E Strategy to Buy 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.
AbbVie (ABBV) Set to Report Q2 Earnings: What to Expect
by Zachary Stutler
AbbVie (ABBV) is set to release its Q2 earnings before market open on Friday. AbbVie stock has performed very poorly YTD, falling 26%.
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
by Zacks Equity Research
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
by Zacks Equity Research
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Top Ranked Value Stocks to Buy for July 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, July 23rd
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $68, marking a -0.79% move from the previous day.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
by Kinjel Shah
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
Should Value Investors Buy AbbVie (ABBV) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.